Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
来源期刊:CNS DrugsDOI:10.1007/s40263-018-0601-x
Mixed States: Modelling and Management
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00609-3
Recent Advances in the Drug Treatment of Dravet Syndrome
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00666-8
Tranexamic Acid in Cerebral Hemorrhage: A Meta-Analysis and Systematic Review
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00608-4
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00642-2
Neurological and Psychiatric Adverse Effects of Antimicrobials
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00649-9
Endolysosome and Autolysosome Dysfunction in Alzheimer’s Disease: Where Intracellular and Extracellular Meet
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00643-1
Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management
来源期刊:CNS DrugsDOI:10.1007/s40263-018-0599-0
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00657-9
Recent Advances in Pharmacotherapy for Episodic Migraine
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00665-9
Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00631-5
Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential
来源期刊:CNS DrugsDOI:10.1007/s40263-018-00602-2
Opioid-Induced Tolerance and Hyperalgesia
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00660-0
Revisiting Tramadol: A Multi-Modal Agent for Pain Management
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00623-5
Novel IDH1-Targeted Glioma Therapies.
来源期刊:CNS drugsDOI:10.1007/s40263-019-00684-6
Rotigotine Transdermal Patch: A Review in Parkinson’s Disease
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00646-y
A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00607-5
Pharmacological Manipulation of the Circadian Clock: A Possible Approach to the Management of Bipolar Disorder
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00673-9
Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case–Control Study Using Automated Health Data Sources
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00611-9
Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00677-5
Comment on: “Phytomedicines in the Treatment of Migraine”
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00635-1
Intravenous Corticosteroids as an Adjunctive Treatment for Refractory and Super-Refractory Status Epilepticus: An Observational Cohort Study
来源期刊:CNS DrugsDOI:10.1007/s40263-018-0600-y
Authors’ Reply to Tsivgoulis et al.: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00616-4
Authors’ Reply to Diener: “Phytomedicines in the Treatment of Migraine”
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00636-0
Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00682-8
Correction to: A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
来源期刊:CNS DrugsDOI:10.1007/s40263-019-00653-z